Viking Therapeutics (VKTX) IPO Opens Modestly Higher

Toay's IPO for Viking Therapeutics (NASDAQ: VKTX) opened for trading at $8.50 after pricing 3,000,000 shares of its common stock at an initial offering price to the public of $8.00 per share.

Laidlaw & Company (UK) Ltd. is acting as the sole book-running manager for the offering. Feltl and Company, Inc. is serving as co-manager for the offering.

Partner Ligand Pharmaceuticals (NASDAQ: LGND) invested $9 million in the offering.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Viking’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives. Viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated. Viking’s clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, entering Phase 2 development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery and VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes. Viking is also developing novel and selective agonists of the thyroid beta receptor for adrenoleukodystrophy and lipid disorders, as well as two earlier-stage programs targeting metabolic diseases and anemia.

You May Also Be Interested In

• Viking Therapeutics (VKTX) Tops Q1 EPS by 2c
• Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
• Loar Holdings (LOAR) Opens At $45, IPO At $28 (earlier)